U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C13H24N4O3S
Molecular Weight 316.42
Optical Activity ( + )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIMOLOL, (R)-

SMILES

CC(C)(C)NC[C@@H](O)COC1=NSN=C1N2CCOCC2

InChI

InChIKey=BLJRIMJGRPQVNF-SNVBAGLBSA-N
InChI=1S/C13H24N4O3S/c1-13(2,3)14-8-10(18)9-20-12-11(15-21-16-12)17-4-6-19-7-5-17/h10,14,18H,4-9H2,1-3H3/t10-/m1/s1

HIDE SMILES / InChI

Molecular Formula C13H24N4O3S
Molecular Weight 316.42
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/8286 | https://www.ncbi.nlm.nih.gov/pubmed/2896241

(R)-Timolol is the (R)-enantiomer of non-selective Beta antagonist Timolol. (R)-Timolol is a ß-adrenergic blocking agent that binds only to nonspecific sites in the particulate fraction of the heart, lungs, and brain. (R)-Timolol is an antihypertensive agent that increases ocular blood flow and reduces intraocular pressure. (R)-Timolol is one of the impurities in commercial formulation of (S)-Timolol.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
26.9 nM [Kd]
13.8 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

In Vivo Use Guide
Rats were treated i.v. with 0.1 mg/kg of (R)-Timolol Rats were treated p.o. with 1-10mg/kg of (R)-Timolol
Route of Administration: Other
In Vitro Use Guide
Rabbit eyes and heart ventricle were from New Zealand albino males, 3 to 6 months old. Chary process villae were separated carefully from any contaminating iris or ciliary body, washed once in 150 mM NaCl and homogenized (10 mg/ml) by hand in an all-glass homogenizer in 6 mM Tris maleate buffer, pH 7.4. Heart tissue was first minced and then homogenized (20-50 mg/ml). Aparticulate (P1) preparation was prepared by diluting the homogenate in 20 volumes of 6 mM Tris maleate buffer, centrifuging at 100,000 x g for 30 min, and resuspending the pellet in the initial volume of buffer used for homogenization. Kinetic constants obtained using the P1 fraction as a source of adenylate cyclase were similar to those obtained using homogenates. Inhibition (by various concentrations of an antagonist) of beta adrenergic receptor-mediated activation of adenylate cyclase activity was used to determine the inhibitory constants. IC50 values were determined utilizing 12 to 16 data points per dose-response curve. For the inhibition curves, various concentrations of antagonist were tested against a fixed concentration of (-)-isoproterenol. Stimulation in the presence of isoproterenol plus antagonist was calculated as the increase over that seen in the presence of antagonist alone.
Substance Class Chemical
Created
by admin
on Sat Dec 16 10:07:07 UTC 2023
Edited
by admin
on Sat Dec 16 10:07:07 UTC 2023
Record UNII
2BG20ZUO2E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIMOLOL, (R)-
Common Name English
D-TIMOLOL
Common Name English
(+)-TIMOLOL
Common Name English
(R)-(+)-TIMOLOL
Common Name English
2-PROPANOL, 1-((1,1-DIMETHYLETHYL)AMINO)-3-((4-(4-MORPHOLINYL)-1,2,5-THIADIAZOL-3-YL)OXY)-, (2R)-
Systematic Name English
TIMOLOL ANHYDROUS, (R)-
Common Name English
L-714465
Code English
TIMOLOL, (+)-
Common Name English
TIMOLOL MALEATE IMPURITY A [EP IMPURITY]
Common Name English
(2R)-1-((1,1-DIMETHYLETHYL)AMINO)-3-((4-(MORPHOLIN-4-YL)-1,2,5-THIADIAZOL-3-YL)OXY)PROPAN-2-OL
Systematic Name English
(R)-TIMOLOL
Common Name English
Code System Code Type Description
PUBCHEM
168613
Created by admin on Sat Dec 16 10:07:07 UTC 2023 , Edited by admin on Sat Dec 16 10:07:07 UTC 2023
PRIMARY
CAS
26839-76-9
Created by admin on Sat Dec 16 10:07:07 UTC 2023 , Edited by admin on Sat Dec 16 10:07:07 UTC 2023
PRIMARY
ECHA (EC/EINECS)
248-033-1
Created by admin on Sat Dec 16 10:07:07 UTC 2023 , Edited by admin on Sat Dec 16 10:07:07 UTC 2023
PRIMARY
FDA UNII
2BG20ZUO2E
Created by admin on Sat Dec 16 10:07:07 UTC 2023 , Edited by admin on Sat Dec 16 10:07:07 UTC 2023
PRIMARY
EPA CompTox
DTXSID801318141
Created by admin on Sat Dec 16 10:07:07 UTC 2023 , Edited by admin on Sat Dec 16 10:07:07 UTC 2023
PRIMARY
CHEBI
39466
Created by admin on Sat Dec 16 10:07:07 UTC 2023 , Edited by admin on Sat Dec 16 10:07:07 UTC 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
not more than the area of the principal peak in the chromatogram obtained with reference solution (d)
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP